Business

AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023

VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs

articleAbcellera Biologics Inc.May 29, 20233/company/abcellera-biologics-inc/news/abcellera-to-present-at-the-goldman-sachs-44th-annual-global-healthcare-conference-on
AbCellera to Present at the Goldman Sachs 44th Annual Global Healthcare Conference on June 13, 2023

About this update from Abcellera Biologics Inc.

[{"type":"text","content":" VANCOUVER, British Columbia--(BUSINESS WIRE)--\nAbCellera (Nasdaq: ABCL) today announced that executives from the Company will present at the Goldman Sachs 44th Annual Global Healthcare Conference in Dana Point, California on Tuesday, June 13, 2023, at 1:20 p.m. Pacific Time (4:20 p.m. Eastern Time).\n\n\nA live audio webcast of the presentation may be accessed through a link that will be posted on AbCellera's Investor Relations website. A replay will be available through the same link following the presentation.\n\n\nAbout AbCellera Biologics Inc.\n\n\nAbCellera is breaking the barriers of conventional antibody discovery to bring better medicines to patients, sooner. AbCellera’s engine integrates expert teams, technology, and facilities with the data science and automation needed to propel antibody-based medicines from target to clinic in nearly every therapeutic area with precision and speed. AbCellera provides innovative biotechs and leading pharmaceutical companies with a competitive advantage that empowers them to move quickly, reduce cost, and tackle the toughest problems in drug development. For more information, please visit www.abcellera.com.\n\nView source version on businesswire.com: https://www.businesswire.com/news/home/20230525005760/en/\n\nInquiries\nMedia: Jessica Yingling, Ph.D.; [email protected], +1(236)521-6774\nBusiness Development: Murray McCutcheon, Ph.D.; [email protected], +1(604)559-9005\nInvestor Relations: Josephine Hellschlienger, Ph.D.; [email protected], +1(778)729-9116\n\n\nSource: AbCellera Biologics Inc.","length":3377,"tagName":"div"}]

More updates from Abcellera Biologics Inc.